section name header

Pronunciation ⬇

LAN-than-um

Classifications ⬆ ⬇

Therapeutic Classification: hypophosphatemics

Pharmacologic Classification: phosphate binders

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Dissociates in the upper GI tract, forming lanthanate ions, which form an insoluble complex with phosphate.
Therapeutic effects:
  • Decreased serum phosphate levels.

Pharmacokinetics ⬆ ⬇

Absorption: Negligible absorption.

Distribution: Stays within the GI tract.

Metabolism/Excretion: Eliminated almost entirely in feces.

Half-Life: 53 hr (in plasma).

Time/Action Profile ⬆ ⬇

(effect on phosphate levels)

ROUTEONSETPEAKDURATION
POunknown2–3 wkunknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

F and E: hypocalcemia

GI: nausea, vomiting, diarrhea, fecal impaction, GI obstruction, GI perforation, ileus

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Fosrenol